Welcome to our dedicated page for Innate Pharma SA SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma SA (IPHA) reported first-half 2026 results marked by a major partnering deal and restructuring. The company entered a strategic partnership with Sobi for lacutamab, triggering a USD 75 million upfront payment on September 16, 2026 and enabling initiation of the TELLOMAK-3 Phase 3 CTCL trial, with first patient targeted in Q1 2027 and potential accelerated approval in Sézary syndrome. Innate is also eligible for up to USD 505 million in additional milestones and tiered double-digit royalties.
During and shortly after the period, Innate completed a €30 million equity financing (17,647,059 new shares at €1.70) and estimates its cash horizon extends to the end of Q1 2028, factoring in the Sobi upfront and this capital increase. As of June 30, 2026, cash, cash equivalents, short-term investments and financial assets were €21.4 million, with net cash of about €0.1 million and financial debt of €20.2 million, while collaboration liabilities related to monalizumab totaled €39.6 million.
Revenue and other income rose to €5.7 million, but Innate recorded a net loss of €19.6 million, albeit improved from €21.3 million a year earlier, helped by reduced operating expenses. R&D spending fell to €16.9 million and G&A to €7.8 million, reflecting workforce reductions and portfolio focus around IPH4502 and late-stage partnered assets.
Innate Pharma SA (IPHA) reported first-half 2026 revenue and other income of €5.7 million, up from €4.9 million a year earlier, and a net loss of €19.6 million versus €21.3 million. Operating expenses fell to €24.7 million (from €30.3 million) as R&D and G&A were reduced following restructuring.
Cash, cash equivalents and financial assets declined to €21.4 million at June 30, 2026 (from €44.8 million at December 31, 2025), with net cash of €0.1 million and collaboration debt of €39.6 million plus €20.1 million of bank borrowings. Operating activities used €21.0 million of cash in the half. Shareholders’ equity was negative at €40.5 million.
The company highlights significant post-period financing: a USD 75 million upfront licensing and commercialization agreement with Sobi for lacutamab and an August 2026 private placement raising about €30 million. After these transactions, management estimates having sufficient liquidity to fund planned operations until the first quarter of 2028, and the financial statements are prepared on a going-concern basis.
Innate Pharma S.A. (IPHA) reports that its previously announced strategic partnership with Sobi for the T‑cell lymphoma drug candidate lacutamab is now effective, following expiration of applicable antitrust waiting periods and completion of other closing conditions. Transaction closing triggers a USD 75 million upfront payment to Innate and the initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T‑cell lymphoma, with first patient expected in Q1 2027. Under the agreement, Innate will conduct TELLOMAK-3 to support applications for full approvals in Sézary syndrome and mycosis fungoides, while Sobi receives exclusive global commercialization rights to lacutamab upon potential accelerated approval and may assume full global development rights after positive Phase 3 results.
Innate Pharma S.A. (IPHA) announced it will host a conference call and webcast on September 17, 2026 to provide a business update for the first half of 2026. The event will feature the company’s senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, and Chief Financial Officer.
Innate Pharma is a clinical-stage biotechnology company focused on immunotherapies for cancer, with a proprietary pipeline centered on antibody-drug conjugates such as IPH4502 targeting Nectin-4, and partnered late-stage assets lacutamab with Sobi and monalizumab with AstraZeneca. The webcast replay will be available for 90 days on the company’s website.
Innate Pharma S.A. (IPHA), a clinical-stage biotechnology company focused on immunotherapies for cancer, reported that members of its executive team will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, United States, on September 14–16, 2026. A fireside chat is scheduled for September 14, 2026 at 4:30 PM EDT / 10:30 PM CEST, with a live webcast and replay accessible via the Investors section of Innate Pharma’s website. The company highlights a pipeline centered on antibody-drug conjugates, led by IPH4502 targeting Nectin-4 for solid tumors, alongside partnered late-stage assets lacutamab with Sobi for cutaneous T-cell lymphomas and monalizumab with AstraZeneca for non-small cell lung cancer.
Innate Pharma S.A. (IPHA) completed a primary private placement of 17,647,059 new ordinary shares at €1.70 per share, raising approximately €30.0 million in gross proceeds through a capital increase without preferential subscription rights under previously approved shareholder resolutions.
After paying placement fees and estimated expenses of about €2.4 million, Innate expects net proceeds of roughly €27.6 million. The shares were placed with qualified institutional buyers in the United States under Section 4(a)(2) of the Securities Act and with qualified and institutional investors outside the United States under Regulation S. The new shares are approved for listing on Euronext Paris on the same line as existing ordinary shares; no new ADSs were issued and the new shares cannot be deposited into the ADS program.
Innate plans to use the net proceeds primarily to continue clinical development of its Nectin-4 ADC IPH4502, advance its preclinical ADC portfolio, and for working capital and general corporate purposes. The company and most directors and certain executives agreed to 90‑day lock‑up restrictions following closing. Separately, management disclosed that existing cash and investments provide runway to the end of Q3 2026, and that, before this offering and assuming a USD 75 million upfront payment from its strategic partnership with Sobi, runway was anticipated to extend through Q3 2027.
Innate Pharma S.A. reports that it will host a conference call and live webcast on August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The event will feature CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations Stéphanie Cornen.
The webcast link and telephone registration are provided, and a replay will be available on the company’s website. Innate describes itself as a global, clinical-stage biotechnology company focused on cancer immunotherapies, with a proprietary pipeline centered on antibody-drug conjugates and partnered late-stage assets in cutaneous T-cell lymphomas and non-small cell lung cancer.
Innate Pharma S.A. entered a strategic partnership with Sobi to support development and potential commercialization of lacutamab for cutaneous T‑cell lymphoma. Innate will run the pivotal TELLOMAK‑3 Phase 3 confirmatory trial in Sézary syndrome and mycosis fungoides, targeting a planned accelerated approval filing in Sézary syndrome based on Phase 2 data.
Under the agreement, Sobi will pay USD 75 million on closing, with Innate eligible for up to USD 40 million in near‑term development milestones and up to USD 465 million in additional option, regulatory and commercial milestones, plus tiered double‑digit royalties on net sales. Innate expects the USD 75 million upfront and near‑term milestones to extend its projected cash runway through Q3 2027, funding TELLOMAK‑3 execution and regulatory filings. Sobi gains exclusive global commercialization rights after potential accelerated approval and may assume full global development rights following positive Phase 3 results. Innate also appointed Markus Jensen as Chief Medical Officer effective September 1, 2026, providing leadership continuity for lacutamab, IPH4502 and monalizumab. Closing of the transaction is subject to customary conditions, including anti‑trust clearance.
Innate Pharma S.A., a clinical-stage biotechnology company developing immunotherapies for cancer patients, announced that its EVP Chief Medical Officer, Sonia Quaratino, will join the bladder cancer panel Changing Treatment Landscape in Bladder Cancer at the BTIG Virtual Biotechnology Conference 2026.
The panel is scheduled for July 28, 2026 at 10:30 a.m. EDT / 4:30 p.m. CEST. Innate Pharma highlights a pipeline of antibody-based therapies, including IPH4502 for solid tumors, lacutamab for cutaneous T cell lymphomas, and monalizumab for non-small cell lung cancer, developed in collaboration with AstraZeneca.
Innate Pharma S.A., a clinical-stage biotechnology company, reports completion of enrollment in the dose-escalation part of its Phase 1 IPH4502-101 study of IPH4502, a proprietary Nectin-4 exatecan antibody-drug conjugate, with 76 patients enrolled in France and the United States.
The study evaluates safety, tolerability and preliminary anti-tumor activity in patients with advanced solid tumors known to express Nectin-4. The company states that IPH4502 continues to show a favorable safety profile with limited hematological toxicity and ongoing preliminary objective responses in urothelial carcinoma post enfortumab vedotin, non-small cell lung cancer and head and neck squamous cell carcinoma. Preliminary data from the dose escalation are expected by year-end to guide Phase 1 dose optimization.